Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen

This article was originally published here

In the Phase 2a study, vupanorsen met the primary endpoint of significant reductions in TG levels and multiple secondary endpoints compared to placebo, with a favorable safety and

The post Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply